Stock Track | Roivant Sciences Plunges 6.11% in Pre-market Following Q2 Earnings Miss and Mixed Pipeline Updates

Stock Track11-10

Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The biopharmaceutical company reported disappointing earnings that fell short of analyst expectations, coupled with mixed updates on its drug pipeline.

The company posted a quarterly revenue of $1.571 million, significantly below the FactSet estimate of $5.6 million. Roivant's net loss for the quarter was $166.039 million, or $0.17 per share, which was better than the expected loss of $0.33 per share. However, the income from operations came in at -$306.233 million, missing the IBES estimate of -$277.8 million.

Despite the earnings miss, Roivant highlighted positive developments in its drug pipeline. The company reported favorable results from its Phase 3 VALOR study of brepocitinib in dermatomyositis, with plans to file a New Drug Application (NDA) in the first half of 2026. Additionally, Roivant's subsidiary Immunovant shared promising data on its treatment for Graves' disease. However, the company announced a delay in reporting results from its thyroid eye disease studies, now expected in the first half of 2026, citing "evolving competitive dynamics." This mixed bag of clinical updates, combined with the financial underperformance, appears to have unsettled investors, leading to the pre-market decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154082935?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154082935","market":"sg","top_or_hot":-1,"title":"Stock Track | Roivant Sciences Plunges 6.11% in Pre-market Following Q2 Earnings Miss and Mixed Pipeline Updates","media":"Stock Track","content":"<p>Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The biopharmaceutical company reported disappointing earnings that fell short of analyst expectations, coupled with mixed updates on its drug pipeline.</p>\n\n<p>The company posted a quarterly revenue of $1.571 million, significantly below the FactSet estimate of $5.6 million. Roivant's net loss for the quarter was $166.039 million, or $0.17 per share, which was better than the expected loss of $0.33 per share. However, the income from operations came in at -$306.233 million, missing the IBES estimate of -$277.8 million.</p>\n\n<p>Despite the earnings miss, Roivant highlighted positive developments in its drug pipeline. The company reported favorable results from its Phase 3 VALOR study of brepocitinib in dermatomyositis, with plans to file a New Drug Application (NDA) in the first half of 2026. Additionally, Roivant's subsidiary Immunovant shared promising data on its treatment for Graves' disease. However, the company announced a delay in reporting results from its thyroid eye disease studies, now expected in the first half of 2026, citing \"evolving competitive dynamics.\" This mixed bag of clinical updates, combined with the financial underperformance, appears to have unsettled investors, leading to the pre-market decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Roivant Sciences Plunges 6.11% in Pre-market Following Q2 Earnings Miss and Mixed Pipeline Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Roivant Sciences Plunges 6.11% in Pre-market Following Q2 Earnings Miss and Mixed Pipeline Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 22:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The biopharmaceutical company reported disappointing earnings that fell short of analyst expectations, coupled with mixed updates on its drug pipeline.</p>\n\n<p>The company posted a quarterly revenue of $1.571 million, significantly below the FactSet estimate of $5.6 million. Roivant's net loss for the quarter was $166.039 million, or $0.17 per share, which was better than the expected loss of $0.33 per share. However, the income from operations came in at -$306.233 million, missing the IBES estimate of -$277.8 million.</p>\n\n<p>Despite the earnings miss, Roivant highlighted positive developments in its drug pipeline. The company reported favorable results from its Phase 3 VALOR study of brepocitinib in dermatomyositis, with plans to file a New Drug Application (NDA) in the first half of 2026. Additionally, Roivant's subsidiary Immunovant shared promising data on its treatment for Graves' disease. However, the company announced a delay in reporting results from its thyroid eye disease studies, now expected in the first half of 2026, citing \"evolving competitive dynamics.\" This mixed bag of clinical updates, combined with the financial underperformance, appears to have unsettled investors, leading to the pre-market decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"","article_id":"1154082935","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154082935","pubTimestamp":1762784905,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd."},"translate_title":"股票追踪|Roivant Sciences在第二季度盈利未达预期和混合管道更新后盘前暴跌6.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1},"content_text":"Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The biopharmaceutical company reported disappointing earnings that fell short of analyst expectations, coupled with mixed updates on its drug pipeline.\nThe company posted a quarterly revenue of $1.571 million, significantly below the FactSet estimate of $5.6 million. Roivant's net loss for the quarter was $166.039 million, or $0.17 per share, which was better than the expected loss of $0.33 per share. However, the income from operations came in at -$306.233 million, missing the IBES estimate of -$277.8 million.\nDespite the earnings miss, Roivant highlighted positive developments in its drug pipeline. The company reported favorable results from its Phase 3 VALOR study of brepocitinib in dermatomyositis, with plans to file a New Drug Application (NDA) in the first half of 2026. Additionally, Roivant's subsidiary Immunovant shared promising data on its treatment for Graves' disease. However, the company announced a delay in reporting results from its thyroid eye disease studies, now expected in the first half of 2026, citing \"evolving competitive dynamics.\" This mixed bag of clinical updates, combined with the financial underperformance, appears to have unsettled investors, leading to the pre-market decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154082935","isCrawlerRequest":true}